The pharmacokinetics of ropivacaine in hepatic and renal insufficiency

Best Practice and Research: Clinical Anaesthesiology

Volumn 19, Issue 2 SPEC. ISS., 2005, Pages 269-274

  Jokinen, Mika J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Kidney diseases; Liver diseases; Pharmacokinetics; Ropivacaine

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; DRUG METABOLITE; ERYTHROMYCIN; FLUVOXAMINE; ITRACONAZOLE; KETOCONAZOLE; ORAL CONTRACEPTIVE AGENT; OROSOMUCOID; ROPIVACAINE;

ARTICLE; BLEEDING; BRACHIAL PLEXUS ANESTHESIA; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG STABILITY; HUMAN; KIDNEY FAILURE; LIVER FAILURE; NERVE CONDUCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGIONAL ANESTHESIA; URINARY EXCRETION;

EID: 17844386065     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2004.12.002     Document Type: Review

References (38)

1. Y.A. Ruetsch T. Boni & A. Borgeat From cocaine to ropivacaine: The history of local anesthetic drugs Curr Top Med Chem 1 2001 175-182
2. A. Markham & D. Faulds Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia Drugs 52 1996 429-449
3. J.H. McClure Ropivacaine Br J Anaesth 76 1996 300-307
4. K.J. McClellan & D. Faulds Ropivacaine: An update of its use in regional anaesthesia Drugs 60 2000 1065-1093
5. B.M. Graf The cardiotoxicity of local anesthetics: The place of ropivacaine Curr Top Med Chem 1 2001 207-214
6. R.D. Wang L.A. Dangler & R.A. Greengrass Update on ropivacaine Expert Opin Pharmacother 2 2001 2051-2063
7. A.N. Plowman S. Bolsin & L.E. Mather Central nervous system toxicity attributable to epidural ropivacaine hydrochloride Anaesth Intensive Care 26 1998 204-206
8. T.I. Ala-Kokko A. Lopponen & S. Alahuhta Two instances of central nervous system toxicity in the same patient following repeated ropivacaine-induced brachial plexus block Acta Anaesthesiol Scand 44 2000 623-626
9. M. Muller R.J. Litz M. Huler & D.M. Albrecht Grand mal convulsion and plasma concentrations after intravascular injection of ropivacaine for axillary brachial plexus blockade Br J Anaesth 87 2001 784-787
10. F. Petitjeans G. Mion M. Puidupin et al. Tachycardia and convulsions induced by accidental intravascular ropivacaine injection during sciatic block Acta Anaesthesiol Scand 46 2002 616-617
11. Y.A. Ruetsch K.E. Fattinger & A. Borgeat Ropivacaine-induced convulsions and severe cardiac dysrhythmia after sciatic block Anesthesiology 90 1999 1784-1786
12. G.T. Tucker Pharmacokinetics of local anaesthetics Br J Anaesth 58 1986 717-731
13. B.M. Emanuelsson J. Persson C. Alm et al. Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers Anesthesiology 87 1997 1309-1317
14. R. Hickey J. Blanchard J. Hoffman et al. Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block Can J Anaesth 37 1990 878-882
15. V.A. Vainionpää E.T. Haavisto T.M. Huha et al. A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block Anesth Analg 81 1995 534-538
16. P. Pere M. Salonen M. Jokinen et al. Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block Anesth Analg 96 2003 563-569
17. A. Lee D. Fagan M. Lamont et al. Disposition kinetics of ropivacaine in humans Anesth Analg 69 1989 736-738
18. E. Arlander G. Ekstrom C. Alm et al. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors Clin Pharmacol Ther 64 1998 484-491
19. M.M. Halldin E. Bredberg B. Angelin et al. Metabolism and excretion of ropivacaine in humans Drug Metab Dispos 24 1996 962-968
20. Jokinen M. Effects of drug interactions and liver disease on the pharmacokinetics of ropivacaine. Academic Dissertation. University of Helsinki. Helsinki; 2003.
21. Y. Oda K. Furuichi K. Tanaka et al. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450 Anesthesiology 82 1995 214-220
22. G. Ekstrom & U.B. Gunnarsson Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes Drug Metab Dispos 24 1996 955-961
23. T. Shimada H. Yamazaki M. Mimura et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1994 414-423
24. M.J. Jokinen J. Ahonen P.J. Neuvonen & K.T. Olkkola The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine Anesth Analg 91 2000 1207-1212
25. M.J. Jokinen K.T. Olkkola J. Ahonen & P.J. Neuvonen Effect of ciprofloxacin on the pharmacokinetics of ropivacaine Eur J Clin Pharmacol 58 2003 653-657
26. M.J. Jokinen J. Ahonen P.J. Neuvonen & K.T. Olkkola Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine Pharmacol Toxicol 88 2001 187-191
27. B.M. Emanuelsson J. Persson S. Sandin et al. Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects Ther Drug Monit 19 1997 126-131
28. P.C. Hayes Liver disease and drug disposition Br J Anaesth 68 1992 459-461
29. S.P. Pereira P.G. Langley & R. Williams The management of abnormalities of hemostasis in acute liver failure Semin Liver Dis 16 1996 403-414
30. C.K. Spiss C.G. Krenn H. Steltzer et al. Anesthesia for patients with liver failure Acta Anaesthesiol Scand Suppl 109 1996 17-20
31. F. Violi R. Leo E. Vezza et al. Bleeding time in patients with cirrhosis: Relation with degree of liver failure and clotting abnormalities C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group J Hepatol 20 1994 531-536
32. A.L. Weigert & A.I. Schafer Uremic bleeding: Pathogenesis and therapy Am J Med Sci 316 1998 94-104
33. T.G. DeLoughery Management of bleeding with uremia and liver disease Curr Opin Hematol 6 1999 329-333
34. D. Mezzano R. Tagle E. Pais et al. Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure Thromb Res 88 1997 465-472
35. K. Höckerstedt S. Kajaste A. Muuronen et al. Encephalopathy and neuropathy in end-stage liver disease before and after liver transplantation J Hepatol 16 1992 31-37
36. J.H. Lee W.J. Jung K.H. Choi et al. Nerve conduction study on patients with severe liver syndrome and its change after transplantation Clin Transplant 16 2002 430-432
37. T. Brismar & R. Tegner Experimental uremic neuropathy Part 2. Sodium permeability decrease and inactivation in potential clamped nerve fibers J Neurol Sci 65 1984 37-45
38. M.Y. Lan S.L. Lai S.S. Chen & D.F. Hwang Tetrodotoxin intoxication in a uraemic patient J Neurol Neurosurg Psychiatry 67 1999 127-128